S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
ETR:BIO

Biotest Aktiengesellschaft (BIO) Stock Forecast, Price & News

€41.70
-0.30 (-0.71%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
€41.30
€42.30
50-Day Range
€41.10
€43.00
52-Week Range
€28.00
€44.60
Volume
456 shs
Average Volume
1,927 shs
Market Capitalization
$825.06 million
P/E Ratio
N/A
Dividend Yield
0.19%
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Biotest Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter.

Biotest Aktiengesellschaft logo

About Biotest Aktiengesellschaft

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

Headlines

Biotest Aktiengesellschaft (ETR:BIO) Stock Price Down 1.7%
Biotest Aktiengesellschaft (ETR:BIO) Shares Down 1.7%
ALCON AG
DGAP-Adhoc: Biotest AG: Biotest exceeds Revenue guidance 2021
Biotest AG: Reduction of guidance
DGAP-Adhoc: Biotest AG: Reduction of guidance
Grifols, S.A. (GRFS)
BIOTEST AG ST O.N. (BIO.MU)
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
1,967
Year Founded
N/A

Sales & Book Value

Annual Sales
$515.60 million
Cash Flow
€2.83 per share
Book Value
€9.61 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$825.06 million
Optionable
Optionable

Company Calendar

Today
5/21/2022
Next Earnings (Estimated)
8/11/2022

MarketRank

Overall MarketRank

0.85 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Biotest Aktiengesellschaft (ETR:BIO) Frequently Asked Questions

When is Biotest Aktiengesellschaft's next earnings date?

Biotest Aktiengesellschaft is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Biotest Aktiengesellschaft
.

Is Biotest Aktiengesellschaft a good dividend stock?

Biotest Aktiengesellschaft pays an annual dividend of €0.04 per share and currently has a dividend yield of 0.19%.

Who are Biotest Aktiengesellschaft's key executives?
Biotest Aktiengesellschaft's management team includes the following people:
  • Dr. Michael Ramroth, Chairman of the Management Board, CEO & CFO (Age 60, Pay $2.1M)
  • Dr. Georg Floß, COO & Member of the Board of Management
  • Dr. Jorg Schuttrumpf, Chief Scientific Officer & Member of the Management Board (Age 48)
  • Dr. Monika Buttkereit, Head of Investor Relations
  • Dr. Christina Erb, Head of Corp. HR
  • Dr. Katrin Bernöster, Head of the Project Management Organisation
  • Mr. Peter Seith, Head of Quality Operations
What other stocks do shareholders of Biotest Aktiengesellschaft own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biotest Aktiengesellschaft investors own include Grifols (GRFS), CSL (CSL), BioXcel Therapeutics (BTAI) and ADMA Biologics (ADMA).

What is Biotest Aktiengesellschaft's stock symbol?

Biotest Aktiengesellschaft trades on the ETR under the ticker symbol "BIO."

What is Biotest Aktiengesellschaft's stock price today?

One share of BIO stock can currently be purchased for approximately €41.70.

How much money does Biotest Aktiengesellschaft make?

Biotest Aktiengesellschaft has a market capitalization of $825.06 million and generates $515.60 million in revenue each year.

How many employees does Biotest Aktiengesellschaft have?

Biotest Aktiengesellschaft employs 1,967 workers across the globe.

What is Biotest Aktiengesellschaft's official website?

The official website for Biotest Aktiengesellschaft is www.biotest.com.

How can I contact Biotest Aktiengesellschaft?

Biotest Aktiengesellschaft's mailing address is Landsteinerstr. 5, DREIEICH, 63303, Germany. The company can be reached via phone at +49-6103-8010.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.